ArticleClinics (Sao Paulo, Brazil)2024
Reduced HDL-cholesterol in long COVID-19: A key metabolic risk factor tied to disease severity.
Article in Clinics (Sao Paulo, Brazil), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.
- Increased Insulin Resistance and Hyperglycaemia in Long COVID: A Systematic Review and Meta-Analysis.Expert reviews in molecular medicine · 2026Pooled it
- Brain corticogenesis promotes SARS-CoV-2 neuro-glial tropism through lipid-dependent viral replication.Stem cell reports · 2026Article
- Insulin Resistance and Inflammation.International journal of molecular sciences · 2026Review
- Serum lipidome remodeling in viral pneumonia: from pathophysiology to therapeutics.Frontiers in immunology · 2026Review
- The Time Course of Serum Iron and Serum Ferritin Concentrations Post-COVID-19 and Influenza Vaccinations.Case reports in infectious diseases · 2026Article
- Post-COVID-19: effects on mental health and metabolic markers in type 2 diabetes.Medicine and pharmacy reports · 2026Article
- Gut Microbial Signatures in Long COVID: Potential Biomarkers and Therapeutic Targets.Infectious diseases and therapy · 2025Article
- Longitudinal lipoprotein and inflammatory mediators analysis uncover persisting inflammation and hyperlipidemia following SARS-CoV-2 infection in long COVID-19.Metabolomics : Official journal of the Metabolomic Society · 2025Article
- High-density lipoproteins and COVID-19: preparing the next pandemic.Journal of lipid research · 2025Review
- Recent advances in nutritional metabolism studies on SARS-CoV-2 infection.Infectious medicine · 2025Review
- SARS-CoV-2 exploits steroidogenic machinery, triggers lipid metabolism for viral replication and induces immune response in Leydig cells of K18-hACE2 mice.Frontiers in cellular and infection microbiology · 2025Article
- Addressing Post-Acute COVID-19 Syndrome in Cancer Patients, from Visceral Obesity and Myosteatosis to Systemic Inflammation: Implications in Cardio-Onco-Metabolism.Biomedicines · 2024Review
- Association between lipid profile and clinical outcomes in COVID-19 patients.Scientific reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This controlled study investigated metabolic changes in non-vaccinated individuals with Long-COVID-19, along with their connection to the severity of the disease. The study involved 88 patients who experienced varying levels of initial disease severity (mild, moderate, and severe), and a control group of 29 healthy individuals. Metabolic risk markers from fasting blood samples were analyzed, and data regarding disease severity indicators were collected. Findings indicated significant metabolic shifts in severe Long-COVID-19 cases, mainly a marked drop in HDL-C levels and a doubled increase in ferritin levels and insulin resistance compared to the mild cases and controls. HDL-C and ferritin were identified as the leading factors predicted by disease severity. In conclusion, the decline in HDL-C levels and rise in ferritin levels seen in Long-COVID-19 individuals, largely influenced by the severity of the initial infection, could potentially play a role in the persistence and progression of Long-COVID-19. Hence, these markers could be considered as possible therapeutic targets, and help shape preventive strategies to reduce the long-term impacts of the disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.